Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

351

HTML

2398

Tables (1-2)

238

Sum=2987

Publishing Process of This Article

Item

Count

Browse

1120

Download

526

Sum=1646

Oct 27, 2013 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Oct 27, 2013; 5(10): 521-527
Published online Oct 27, 2013. doi: 10.4254/wjh.v5.i10.521

Table 1 Worst evolution (negative events altogether evaluated) and hepatocellular carcinoma incidence in interferon treated patients n (%)

^bP < 0.01 vs non responder (NR). SR: Sustained responder; RR: Relapse responder; HCC: Hepatocellular carcinoma.

Citation: Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol 2013; 5(10): 521-527
URL: https://www.wjgnet.com/1948-5182/full/v5/i10/521.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i10.521